Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa Clinical Trial

— HIDRA  

Official title:

A Randomized Controlled Trial to Evaluate the Efficacy of Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04325607
• Other study ID #: 247179
• Status: Terminated
• Phase: N/A
• Start date: September 1, 2019
• Est. completion date: October 1, 2023

Study information

• Verified date: December 2023
• Source: Royal Free Hospital NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect. The soft tissue defect will then be managed with Negative Pressure Wound Therapy (NPWT) to promote healthy granulation tissue formation for wound coverage with Split skin graft (SSG). This long interval between excision and reconstruction could result in long in-patient stay, increased risk of hospital acquired infection and reduced patients' quality of life.

The investigators wish to evaluate the use of Negative Pressure Wound Therapy with instillation (NPWTi), which has potential to allow early wound coverage with SSG, as an alternative to the current standard of care. The investigators hypothesise that NPWTi reduces bacterial load on the wound and allows early wound coverage hence improves patient satisfaction and reduces cost and length of hospital stay.

Description:

HS is a recurring chronic skin disease of the hair follicle that usually presents with painful and inflamed lesions in the sweat gland-bearing areas of the body. The lesions often progress to become chronic with pus discharge and scar formation resulting in significant disability.

Current surgical management for severe HS involves surgical removal of all involved hair bearing skin resulting in large areas of soft tissue loss which requires reconstruction. The wound is reconstructed by performing skin grafting, known as SSG, whereby a healthy layer of skin is transferred to the area of tissue loss. SSG enables rapid wound healing and has low risk of recurrence of HS. Skin grafting is often done a few weeks after excision of HS (delayed setting) to ensure higher success rate due to the infected nature of HS. During the interval between surgical removal of areas with HS and skin grafting, the wound is managed with a suction dressing known as the Negative Pressure Wound Therapy (NPWT) to promote formation of healthy wound bed. NPWT is a form of vacuum dressing which applies continuous suction pressure on the wound to remove fluids and bacteria from the wound bed.

The NPWT is highly successful in managing such wounds, however a novel and innovative improvement to this technology with an irrigation system, the Negative Pressure Wound Therapy with instillation (NPWTi), holds promise to enhance production of healthy wound bed and further reducing bacteria and infectious materials from the wound, enabling earlier wound coverage with SSG. The NPWTi involves irrigating and soaking the wound with fluid, followed by removal of the fluid via application of suction pressure at timed, regular intervals. The goal of the instillation therapy is to enable early application of SSG as wound irrigation has long been appreciated as beneficial for cleaning contaminated wounds.

The investigators wish to evaluate the NPWTi as an alternative to NPWT for current surgical management strategy of severe HS. The investigators wish to determine if NPWTi allows early wound coverage with SSG which improves patient satisfaction and reduces length of hospital stay. This research will further our knowledge about the human wound healing process and it may help improve treatment for future patients. The investigators plan to study up to 44 patients in total.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: October 1, 2023
• Est. primary completion date: October 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Male and female

2. Age 18-90 at the time of consent

3. Clinical diagnosis of axillary hidradenitis suppurativa

4. Unilateral axillary hidradenitis suppurativa (if bilateral disease, only one side will be included into study).

5. Hidradenitis suppurativa with multiple sinuses which are not able to close directly

6. Not on antibiotics for 6 weeks

7. Patient understands and is willing to participate

Exclusion Criteria:

1. Hidradenitis suppurativa with isolated sinus for direct closure

2. Patient with ongoing chemotherapy or radiotherapy

3. Patient with active cancer

4. Uncontrolled Diabetes Mellitus, as measured by an HbA1c > 10%.

5. BMI over 35

6. Active smoker

7. Presence of one or more medical conditions, including renal, hepatic, hematologic, active auto-immune or immune diseases that, would make the subject an inappropriate candidate for this wound healing study

8. Patient not fit for surgery (ASA classification > 4)

9. Patients not able to consent for procedure in English

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa

Intervention

Procedure:
• Excision of HS followed by NPWTi
The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
• Excision of HS followed by NPWT
The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)

Locations

Country	Name	City	State
United Kingdom	Royal Free NHS Foundation Trust Hospital London	London

Sponsors (2)

Lead Sponsor	Collaborator
Royal Free Hospital NHS Foundation Trust	KCI Europe Holding B.V.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The mean days to wound coverage with split skin graft (SSG) after excision of HS	Mean days to wound coverage with split skin graft (SSG) after excision of HS in each treatment arm	2 weeks
Primary	The difference in bacterial count on the wound after NPWTi against NPWT	Reduction in the number of colony-forming unit (CFU) at each dressing change analysed using tissue culture of wound bed biopsies	2 weeks
Secondary	Proportion of wounds covered with SSG at 1 week post excision	The proportion of wounds (in percentage) covered with split skin graft at 1 week post excision.	1 week
Secondary	Percentage of graft take at week 1 and week 4	Percentage of skin graft survival at week 1 and week 4	4 weeks
Secondary	Number of patients with recurrence of HS at 3 and 6 months	Number of patients with recurrence of disease at 3 and 6 months	6 months
Secondary	Number of patients with improved Dermatology Life Quality Index (DLQI)	Dermatology Life Quality Index (DLQI) will be used to measure the improvement in quality of life. Comparison will be made between DLQI during pre operative period and 6 months post operative	6 months
Secondary	The difference in cost between both treatments	Data on the total cost of treatment between both treatment groups will be compared. The total cost will combine the cost of procedures, cost of devices, cost of inpatient stay and cost of clinic follow ups.	6 months